Latest filings (excl ownership)
8-K
BioAmber Provides Update on Liquidation Process
26 Oct 18
8-K
BioAmber Provides Update on Liquidation ProcessĀ & Announces Resignations
4 Sep 18
8-K
BioAmber Provides Update on Liquidation Process
14 Aug 18
8-K
BioAmber Provides Update on Sales Process
1 Aug 18
8-K
BioAmber Receives Favourable Court Ruling and Approval for DIP Financing
20 Jun 18
NT 10-Q
Notice of late quarterly filing
9 May 18
8-K
BioAmber Announces Filing for Stay of Proceedings on Creditors
8 May 18
10-K/A
2017 FY
Annual report (amended)
30 Apr 18
DEFA14A
Additional proxy soliciting materials
16 Apr 18
10-K
2017 FY
Annual report
30 Mar 18
DEF 14A
Definitive proxy
30 Mar 18
PRE 14A
Preliminary proxy
20 Mar 18
NT 10-K
Notice of late annual filing
15 Mar 18
25-NSE
Exchange delisting
27 Feb 18
8-K
BioAmber Inc. Receives Notice of Delisting by TSX
16 Feb 18
8-K
BioAmber Inc. Receives Notice of Delisting Review by TSX
15 Feb 18
424B5
Prospectus supplement for primary offering
13 Feb 18
8-K
BioAmber Inc. Announces Registered Direct Offering; Termination of Underwriting Agreement for Previously-Announced Public Offering
13 Feb 18
424B5
Prospectus supplement for primary offering
9 Feb 18
424B5
Prospectus supplement for primary offering
8 Feb 18
8-K
Bioamber Inc. Announces Pricing of US$10 Million Underwritten Public Offering
8 Feb 18
UPLOAD
Letter from SEC
7 Feb 18
424B5
Prospectus supplement for primary offering
6 Feb 18
8-K/A
Regulation FD Disclosure
6 Feb 18
424B5
Prospectus supplement for primary offering
5 Feb 18
8-K
Bioamber Inc. Announces Underwritten Offering
5 Feb 18
8-K
Entry into a Material Definitive Agreement
26 Jan 18
CORRESP
Correspondence with SEC
17 Jan 18
UPLOAD
Letter from SEC
28 Nov 17
10-Q
2017 Q3
Quarterly report
8 Nov 17
8-K
BioAmber Announces Third Quarter 2017 Financial Results
8 Nov 17
CORRESP
Correspondence with SEC
27 Oct 17
8-K
Entry into a Material Definitive Agreement
24 Oct 17
UPLOAD
Letter from SEC
27 Sep 17
8-K
BioAmber Announces New Chief Executive Officer
14 Sep 17
8-K
BioAmber Inc. Receives Notice of Non-Compliance from the NYSE
13 Sep 17
8-K
Entry into a Material Definitive Agreement
11 Aug 17
424B5
Prospectus supplement for primary offering
9 Aug 17
424B5
Prospectus supplement for primary offering
8 Aug 17
10-Q
2017 Q2
Quarterly report
4 Aug 17
Latest ownership filings
SC 13G/A
BioAmber Inc.
8 Aug 19
SC 13G/A
BioAmber Inc.
8 Aug 19
SC 13G/A
BioAmber Inc.
25 Jul 19
SC 13G/A
BioAmber Inc.
19 Jul 19
SC 13G
BioAmber Inc.
10 Jul 19
SC 13G
BioAmber Inc.
9 Jul 19
SC 13D/A
BioAmber Inc.
14 Feb 19
SC 13G/A
BioAmber Inc.
8 Feb 19
SC 13G/A
BioAmber Inc.
3 Jan 19
SC 13G/A
BioAmber Inc.
7 Jun 18
4
Richard P Eno
3 Apr 18
SC 13G/A
BioAmber Inc.
9 Mar 18
SC 13G
BioAmber Inc.
20 Feb 18
SC 13G
BioAmber Inc.
16 Feb 18
SC 13G
BioAmber Inc.
14 Feb 18
SC 13G/A
BioAmber Inc.
9 Jan 18
4
Kenneth W. Wall
4 Dec 17
SC 13G/A
BioAmber Inc.
10 Oct 17
4
Richard P Eno
5 Oct 17
3
Richard P Eno
28 Sep 17
SC 13G
BioAmber Inc.
12 Sep 17
SC 13G
BioAmber Inc.
8 Sep 17
SC 13G/A
BioAmber Inc.
8 Sep 17
4
Michael A. Hartmann
22 Aug 17
4
Fabrice Orecchioni
16 Aug 17
4
ELLEN B RICHSTONE
16 Aug 17
4
Mario Settino
16 Aug 17
4
RAYMOND J LAND
16 Aug 17
4
KURT W BRINER
16 Aug 17
4
RAYMOND J LAND
16 Aug 17
4
Heinz Haller
16 Aug 17
4
Michael A. Hartmann
16 Aug 17
4
James Millis
16 Aug 17
4
Mario Settino
11 Aug 17
4
Mario Settino
9 Jun 17
4
Robert Frost
9 Jun 17
3
Mario Settino
8 Jun 17
3
Robert Frost
8 Jun 17
4
Heinz Haller
17 May 17
4
Kenneth W. Wall
17 May 17